# INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

> **NCT05904743** · PHASE4 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 141 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** Afrezza
- **BIOLOGICAL:** insulin degludec
- **BIOLOGICAL:** Rapid-acting Insulin Analog
- **BIOLOGICAL:** Basal Insulin

## Key facts

- **NCT ID:** NCT05904743
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-07
- **Primary completion:** 2024-03-26
- **Final completion:** 2024-06-24
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2024-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904743, "INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05904743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*